Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from Remicade to infliximab biosimilar in RA, SpA, and PsA
NL-OMON24401Active, not recruiting
- Sponsor
- Participating hospitals are: Sint Maartenskliniek Nijmegen Maartenskliniek Woerden Radboud University Medical Centre Nijmegen Rijnstate Arnhem
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of infliximab in rheumatoid arthritis (RA), spondyloarthritis (SpA) and psoriatic arthritis (PsA) (2 arms), sponsored by Participating hospitals are: Sint Maartenskliniek Nijmegen Maartenskliniek Woerden Radboud University Medical Centre Nijmegen Rijnstate Arnhem. Primary endpoint: Change in disease activity scores. Started Jul 2015; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)spondyloarthritis (SpA)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON24401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24401.